Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.
The Food and Drug Administration (FDA) approved Tarceva for 2nd/3rd-line treatment of advanced Non-Small Cell Lung Cancer (NSCLC) on November 18, 2004. In April 2010, Tarceva was approved by the FDA as maintenance therapy for patients with advanced-stage NSCLC. For more information see the FDA Approval Letter.
